GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » 3-Year RORE %

CERT (Certara) 3-Year RORE % : 37.39% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Certara 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Certara's 3-Year RORE % for the quarter that ended in Sep. 2024 was 37.39%.

The industry rank for Certara's 3-Year RORE % or its related term are showing as below:

CERT's 3-Year RORE % is ranked better than
79.28% of 613 companies
in the Healthcare Providers & Services industry
Industry Median: -0.25 vs CERT: 37.39

Certara 3-Year RORE % Historical Data

The historical data trend for Certara's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara 3-Year RORE % Chart

Certara Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial - - - -125.48 78.49

Certara Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.63 78.49 80.73 98.20 37.39

Competitive Comparison of Certara's 3-Year RORE %

For the Health Information Services subindustry, Certara's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Certara's 3-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Certara's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Certara's 3-Year RORE % falls into.



Certara 3-Year RORE % Calculation

Certara's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.2--0.034 )/( -0.444-0 )
=-0.166/-0.444
=37.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Certara  (NAS:CERT) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Certara 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Certara's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Certara Business Description

Traded in Other Exchanges
Address
100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Executives
Patrick F Smith officer: PRESIDENT, INTEGRATED DRUG DEV C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Leif E Pedersen officer: President, Software 10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Richard M. Traynor officer: See Remarks 1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Eran Broshy director C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
John E Gallagher officer: CHIEF FINANCIAL OFFICER BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p. 10 percent owner 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight director 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine director 2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905